Product Description
Mechanisms of Action: D2 Antagonist,5-HT2A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | Czech | Denmark | Estonia | Iceland | Ireland | Latvia | Lithuania | Portugal | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Lundbeck
Company Location: DENMARK G7 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Tic Disorders|Dementia|Psychophysiologic Disorders|Other|Schizophrenia|Depressive Disorder
Phase 2: Parkinson's Disease|Psychotic Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TDM-VIGIL | P3 |
Completed |
Other |
2018-12-31 |
|
GAP | P3 |
Terminated |
Depressive Disorder|Dementia|Psychophysiologic Disorders|Tic Disorders|Schizophrenia |
2017-06-28 |
|
13104A | P2 |
Completed |
Parkinson's Disease|Psychotic Disorders |
2008-03-01 |